πŸ”¬ Third-party verified peptides Β· Free Express Post over $200 CAD
Pantheon Peptides
Muscle Growth5 cited studies

CJC-1295 with DAC

Long-acting GHRH analog with Drug Affinity Complex β€” once or twice-weekly GH support.

Also known as: CJC-1295 DAC Β· CJC 1295 DAC
SummaryMechanismDosingSafetyStudies
Research use only β€” not for human consumption.

What it is

CJC-1295 with DAC is a long-acting GHRH analog designed to boost the body's natural production of growth hormone. The addition of DAC (Drug Affinity Complex) extends its half-life to several days, enabling sustained release with fewer injections. Favored for lean muscle support, fat reduction, recovery, deeper sleep, and anti-aging effects on skin, cellular repair, and bone density.

Mechanism of action

Binds GHRH receptors on the anterior pituitary; the DAC moiety covalently binds plasma albumin, dramatically extending half-life. Continuous GHRH receptor stimulation elevates baseline GH and IGF-1 with retained (though dampened) pulsatility.

Half-life: ~6–8 days (with DAC) β€” supports twice-weekly dosing.

Evidence summary

Healthy-adult Phase 1/2 trials (Teichman 2006) demonstrated sustained GH and IGF-1 elevation over 28 days with weekly dosing. GHRH knockout mouse and bioconjugate work establish the long-acting GRF mechanism.

Typical dosing protocols

Typical dose
1000–2000 mcg
Frequency
2x per week
Cycle length
12 weeks
  • 1–2 mg subcutaneous, twice weekly (typical)
  • Often paired with Ipamorelin for synergistic GH pulse
  • 12-week cycles with at least 4 weeks off between

Side effects & safety

  • Mild injection-site irritation or flushing
  • Tingling, head-rush, or transient fatigue
  • Water retention or carpal tunnel-like symptoms at higher chronic doses

Cited studies

  1. Teichman SL, Neale A, Lawrence B, et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism.
    PMID 16352683Read source β†—
  2. Ionescu M, Frohman LA (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism.
    PMID 16940451Read source β†—
  3. JettΓ© L, LΓ©ger R, Thibaudeau K, et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology.
    PMID 15890776Read source β†—
  4. Alba M, Fintini D, Bowers CY, et al. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology β€” Endocrinology and Metabolism.
    PMID 16835400Read source β†—
  5. (2009). Activation of the GH/IGF-1 axis by CJC-1295, a long acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research.
    Read source β†—
Disclaimer

All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.

CJC-1295 with DAC β€” Reference, Dosing & Cited Studies | Pantheon Peptides